Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease.

Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V.

PLoS One. 2010 Apr 1;5(4):e9979. doi: 10.1371/journal.pone.0009979. Erratum in: PLoS One. 2011;6(11). doi:10.1371/annotation/05c1b976-7eab-4154-808d-0526e604b8eb.

2.

Over-expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's-like deficits in mice modeling the disease.

Pierce A, Podlutskaya N, Halloran JJ, Hussong SA, Lin PY, Burbank R, Hart MJ, Galvan V.

J Neurochem. 2013 Mar;124(6):880-93. doi: 10.1111/jnc.12080. Epub 2012 Dec 26.

3.

Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?

Cai Z, Zhao B, Li K, Zhang L, Li C, Quazi SH, Tan Y.

J Neurosci Res. 2012 Jun;90(6):1105-18. doi: 10.1002/jnr.23011. Epub 2012 Feb 16. Review.

PMID:
22344941
4.

Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.

Caccamo A, Majumder S, Richardson A, Strong R, Oddo S.

J Biol Chem. 2010 Apr 23;285(17):13107-20. doi: 10.1074/jbc.M110.100420. Epub 2010 Feb 23.

5.

Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.

Caccamo A, De Pinto V, Messina A, Branca C, Oddo S.

J Neurosci. 2014 Jun 4;34(23):7988-98. doi: 10.1523/JNEUROSCI.0777-14.2014.

6.

Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease.

Li L, Zhang S, Zhang X, Li T, Tang Y, Liu H, Yang W, Le W.

Curr Alzheimer Res. 2013 May 1;10(4):433-41.

PMID:
23305067
7.

Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD.

Tramutola A, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, Perluigi M, Butterfield DA.

J Neurochem. 2015 Jun;133(5):739-49. doi: 10.1111/jnc.13037. Epub 2015 Feb 26.

8.

How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story.

Richardson A, Galvan V, Lin AL, Oddo S.

Exp Gerontol. 2015 Aug;68:51-8. doi: 10.1016/j.exger.2014.12.002. Epub 2014 Dec 3. Review.

9.

mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.

Caccamo A, Magrì A, Medina DX, Wisely EV, López-Aranda MF, Silva AJ, Oddo S.

Aging Cell. 2013 Jun;12(3):370-80. doi: 10.1111/acel.12057. Epub 2013 Mar 24.

10.

Rapamycin and mTOR inhibitors probably have therapeutic effects for post-operative cognitive dysfunction.

Yang C, Zhu B, Shen J, Hu T, Li Z, Hong T.

Med Hypotheses. 2013 Sep;81(3):487-8. doi: 10.1016/j.mehy.2013.06.017. Epub 2013 Jul 11.

PMID:
23850396
11.

Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism.

Caccamo A, Maldonado MA, Majumder S, Medina DX, Holbein W, Magrí A, Oddo S.

J Biol Chem. 2011 Mar 18;286(11):8924-32. doi: 10.1074/jbc.M110.180638. Epub 2011 Jan 25.

12.

PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.

O' Neill C.

Exp Gerontol. 2013 Jul;48(7):647-53. doi: 10.1016/j.exger.2013.02.025. Epub 2013 Mar 5. Review.

PMID:
23470275
13.

Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice.

Halloran J, Hussong SA, Burbank R, Podlutskaya N, Fischer KE, Sloane LB, Austad SN, Strong R, Richardson A, Hart MJ, Galvan V.

Neuroscience. 2012 Oct 25;223:102-13. doi: 10.1016/j.neuroscience.2012.06.054. Epub 2012 Jun 28. Erratum in: Neuroscience. 2015 Oct 15;306():151.

14.

A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.

Wei L, Yang H, Xie Z, Yang S, Yang H, Zhao C, Wang P, Xu S, Miao J, Zhao B, Bi J.

J Alzheimers Dis. 2012;30(3):531-43. doi: 10.3233/JAD-2012-111985.

PMID:
22451314
15.

Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in cellular and animal models of Alzheimer's disease.

Jiang T, Yu JT, Zhu XC, Tan MS, Wang HF, Cao L, Zhang QQ, Shi JQ, Gao L, Qin H, Zhang YD, Tan L.

Pharmacol Res. 2014 Mar;81:54-63. doi: 10.1016/j.phrs.2014.02.008. Epub 2014 Mar 3.

PMID:
24602800
16.

Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease.

Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK.

PLoS One. 2010 Sep 20;5(9). pii: e12845. doi: 10.1371/journal.pone.0012845.

17.

Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits.

Majumder S, Richardson A, Strong R, Oddo S.

PLoS One. 2011;6(9):e25416. doi: 10.1371/journal.pone.0025416. Epub 2011 Sep 28.

18.

Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease.

Lin AL, Zheng W, Halloran JJ, Burbank RR, Hussong SA, Hart MJ, Javors M, Shih YY, Muir E, Solano Fonseca R, Strong R, Richardson AG, Lechleiter JD, Fox PT, Galvan V.

J Cereb Blood Flow Metab. 2013 Sep;33(9):1412-21. doi: 10.1038/jcbfm.2013.82. Epub 2013 Jun 26.

19.

Targeting the mTOR signaling network for Alzheimer's disease therapy.

Wang C, Yu JT, Miao D, Wu ZC, Tan MS, Tan L.

Mol Neurobiol. 2014 Feb;49(1):120-35. doi: 10.1007/s12035-013-8505-8. Epub 2013 Jul 14. Review.

PMID:
23853042
20.

Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies.

Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, Eldar-Finkelman H.

J Biol Chem. 2013 Jan 11;288(2):1295-306. doi: 10.1074/jbc.M112.409250. Epub 2012 Nov 15.

Items per page

Supplemental Content

Write to the Help Desk